Alzheimer's disease (AD) is a neurodegenerative condition and the leading cause of dementia worldwide [1]. Currently, AD does not have a curative therapy; this lack of disease-modifying pharmaceuticals has stimulated interest in repurposing existing and approved compounds with the potential to manage AD or delay its onset [2-4]. Metabolic disruption, such as insulin resistance, has become more prominent as a causal factor in AD development, also referred to as "type 3 diabetes" [5-7]. This evidence concerns the gene INS and Alzheimer disease.